Routinely used predictive features, including clinicopathological parameters (age, tumor size, lymph node status, and histological grade) and biomarkers (ER, PR, and HER2) are insufficient for personalized clinical decisions in BC patients (3). The gene discussed is ERBB2; the disease is breast cancer.